Tiburio Therapeutics
Tiburio is a privately-held biopharma focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases.
It is the third company to be launched by the USA-based orphan drug accelerator, Cydan, and is advancing two compounds licensed from French drugmaker Ipsen, TBR-760 for the treatment of non-functioning pituitary adenoma and TBR-065 for additional rare endocrine diseases.
As part of the launch, Tiburio raised a $31 million series A financing.
Latest Tiburio Therapeutics News & Features
3 January 2019
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze